蛇毒血凝酶质控关键技术研究进展

doi:10.19803/j.1672-8629.20230228

中国药物警戒 ›› 2023, Vol. 20 ›› Issue (10): 1195-1200.
DOI: 10.19803/j.1672-8629.20230228

• 综述 • 上一篇

蛇毒血凝酶质控关键技术研究进展

刘博^1,2, 郭云霄^1,2,3,△, 刘莉莎^1,2, 范慧红^1,2,*

¹中国食品药品检定研究院,北京 102629;
²国家药品监督管理局化学药品质量研究与评价重点实验室,北京 102629;
³中国药科大学药学院,江苏南京 210009

收稿日期:2023-04-13 出版日期:2023-10-15 发布日期:2023-10-16
通讯作者: ^*范慧红,女,研究员,生化药物分析。E-mail: shenghuayaoshi@162.com
作者简介:刘博,男,博士,副研究员,生化药物分析。^△为并列第一作者。
基金资助:
北京市自然科学基金资助项目（7194337）

Research progress in key technologies for quality control of snake venom hemocoagulase drugs

LIU Bo^1,2, GUO Yunxiao^1,2,3,△, LIU Lisha^1,2, FAN Huihong^1,2,*

¹National Institutes for Food and Drug Control, Beijing 102629, China;
²NMPA Key Laboratory for Quality Research and Evaluation of Chemical Drugs, Beijing 102629, China;
³School of Pharmacy, China Pharmaceutical University, Nanjing Jiangsu 210009, China

Received:2023-04-13 Online:2023-10-15 Published:2023-10-16

摘要/Abstract

摘要： 近年来,随着蛇毒血凝酶在临床中的广泛应用,对其产品质量的要求也在不断提高。但受限于产品的复杂性以及技术手段的制约,其质控关键技术的发展,尤其是结构表征、纯度分析以及效价测定等质控项目越来越难以满足日趋严格的质控要求。本综述参考了国内外药典和其他蛋白类药物的最新研究进展,对蛇毒血凝酶药物的结构特征、纯度以及效价测定方法进行系统的总结和展望,希望能够对血凝酶类药品质控水平的全面提升提供参考。

关键词: 血凝酶, 质量控制, 一级结构, 高级结构, 纯度, 活性, 蛇毒

Abstract: With the wide application of snake venom hemocoagulase in clinical practice in recent years, better quality of its products is required. However, constrained by the complexity of the products and related technologies, it becomes increasingly difficult for the key quality control technologies, especially quality control projects such as structural characterization, purity analysis and potency, to meet the requirements of increasingly stringent quality control. By referring to domestic and foreign pharmacopoeias and the latest research progress in other proteinic drugs, this article summarizes the structural characteristics, purity and potency determination methods of snake venom hemocoagulase drugs before future developments are predicted. It is hoped that this article can be of referential value for the improvement of levels of quality control of hemocoagulase drugs.

Key words: hemocoagulase, quality control, primary structure, advanced structure, purity, activity, snake venom

中图分类号:

刘博, 郭云霄, 刘莉莎, 范慧红. 蛇毒血凝酶质控关键技术研究进展[J]. 中国药物警戒, 2023, 20(10): 1195-1200.

LIU Bo, GUO Yunxiao, LIU Lisha, FAN Huihong. Research progress in key technologies for quality control of snake venom hemocoagulase drugs[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1195-1200.

参考文献

[1] CHEN JZ.Research and application of snake venom[J]. Journal of Snake(蛇志), 1989, 1(1) : 22-23.
[2] FU HY, ZHOU L.Research progress of snake venom thrombin[J]. Chinese Pharmaceutical Journal(中国药学杂志), 2008, 43(4) : 245-247.
[3] ICH Expert Working Group. ICH harmonised tripartite guideline specifications : test procedures and acceptance criteria for biotechnological/biological products[EB/OL]. (1993-03-10) [2021-11-08]. https://www.fda.gov/media/71510/download.
[4] TANG YL, HUANG M, HU QP, et al.Agkihpin, a distinct SVTLE from the venom of gloydius halys pallas : purifiation, characterization and structure activity determination[J]. Chemistry&Biodiversity, 2018, 15: e1800122.
[5] XIAN RQ, WANG CC, GONG LP, et al.A species specific strategy forthe Identification of hemocoagulase agkistrodon halys pallas Based on LC-MS/MS-MRM frontiers in molecular biosciences[J]. Original Research, 2022, 9 : 831293.
[6] MIMURA Y, SALDOVA R, MIMURA-KIMURA Y, et al.Micro-heterogeneity of antibody molecules[J]. Antibody Glycosylation, 2021, 112 : 1-26.
[7] GREENFIELD NJ.Using circular dichroism spectra to estimate protein secondary structure[J]. Nat Protoc, 2006, 1(6): 2876-2890.
[8] Chinese Pharmacopoeia Commission.Pharmacopoeia of People's Republic of China 2020
(中华人民共和国药典2020年版)[M]中华人民共和国药典2020年版)[M]. Beijing: China Medical Science Press, 2020.
[9] JIA SH, WANG MM.Separation and purification of haemocoagulase from agkistrodon blomhoffii in Changbai mountain[J]. China Pharmacist(中国药师), 2017, 20(2) : 212-215.
[10] LIU B, ZHANG T, HUANG L, et al.Determination of 7 N-nitrosoamines in metformin hydrochloride sustained release tablets by LC-HRMS[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(5): 454-468.
[11] TAN HP, WANG YJ, ZOU Y, et al.Methods of molecular weight determination of proteins[J]. China Measurement & Test(中国测试), 2011, 37(2): 34-37.
[12] HENRY S, ASISH C, YU Y, et al.Structural characterization of the therapeutic monoclonal antibody trastuzumab by LC /MS and LC /MS^E[J]. Chinese Journal of New Drugs(中国新药杂志), 2014, 23(4) : 418-431.
[13] GUI F, YANG LL, PAN YB, et al.Establishment and validation of an LC/MS peptide mapping method for the characterization of anti-TNF-α monoclonal antibody[J]. Chinese Journal of Pharmaceutical Analysis(药物分析杂志), 2017, 37(1): 51-63.
[14] WU G, WANG WB, YU CF, et al.Comprehensive characterization of anti-CTLA4 monoclonal antibody by liquid chromatography high resolution mass spectrometry[J]. Chinese Pharmaceutical Journal(中国药学杂志), 2020, 55(6): 457-464.
[15] LIU HL, REN WC, ZONG L, et al.Pepsin digestion combined with post-column online reduction for analysis of disulfide bonds in recombinant human granulocyte stimulating factor[J]. Chinese Journal of Analytical Chemistry(分析化学), 2019, 47(4): 508-518.
[16] KAUR H.Characterization of glycosylation in monoclonal antibodies and its importance in therapeutic antibody development[J]. Critical Reviews in Biotechnology, 2021, 41(2): 300-315.
[17] LIU XY, CHANG JL, LIU YL.Current status and progress in research of glycosylation modification of monoclonal antibody[J]. Chinese Journal of Biologicals, 2020, 33(2): 216-221.
[18] LI ML, ZHU WW, ZHANG JL.N-glycans and intact glycopeptide-based characterization of N-glycosylation of monoclonal antibody drugs[J]. Acta Pharmaceutica Sinica(药学学报), 2021, 56(9): 2360-2366.
[19] WANG WB, YU CF, et al.Analysis of N-linked glycan profile of therapeutic antibodies by UPLC-QDA MS[J]. Chinese Pharmaceutical Journal(中国药学杂志), 2018, 53(3): 223-227.
[20] DING J, QIAN JQ.Methods for characterizing the secondary and tertiary structures of proteins[J], Zhejiang Chemical Industry(浙江化工), 2022, 51(11): 49-54.
[21] U.S.Pharmacopoeia Convention. U.S. Pharmacopoeia 43[M]. The United States Pharmacopeial Convention, 2020.
[22] CHENG SY, WANG CZ, LI J, et al.Study on the purity analysis method of hemocoagulase[J]. Chinese Journal of Pharmaceutical Analysis(药物分析杂志), 2012, 32(8): 1398-1401.
[23] ZHANG XL, CUI Y, CUI AS, et al.Purification and quality of Wusuli haemocoagulase[J]. China Medical Herald(中国医药导报), 2017, 14(1): 20-23.
[24] WANG WB, YU CF, ZHANG F, et al.Establishment of capillary zone electrophoresis method for charge heterogeneity analysis of IgG2 monoclonal antibody[J]. Chinese Pharmaceutical Journal(中国药学杂志), 2018, 53(8): 627-631.
[25] MARK S, CRUZADO-PARK I, CHAPMAN J, et al.A systematic study in CIEF: Defining and optimizing experimental parameters critical to method reproducibility and robustness[J]. Electrophoresis, 2009, 30 : 4049-4058.
[26] LI X, SHI XC, QIN X, et al.Interlaboratory method validation of imaged capillary isoelectric focusing methodology for analysis of recombinant human erythropoietin[J]. Royal Society of Chemistry, 2020,12: 3836-3843.
[27] LIU XL, CHEN L, DENG YP, et al.Application of ion exchange chromatography in protein separation[J]. Feed Research(饲料检测), 2013, 10(3): 71-73.
[28] DU YY, WU FJ, HAN H, et al.Determination of the purity of recombinant human serum albumin interferon α 2b fusion protein using ion exchange HPLC[J]. Chinese Journal of Pharmaceutical Analysis(药物分析杂志), 2020, 40(8): 1490-1493.
[29] HONG WW, ZHOU FY, FU MJ, et al.Development of a method for determination of purity in tuberculosis therapeutic DNA vaccine based on ion exchange chromatography[J]. Journal of Pharmaceutical Research(药学研究), 2022, 39(11): 628-631.
[30] Pharmaceuticals and Medical Devices Agency of Japan. The Japanese Pharmacopoeia[M]. 17th ed, Tokyo: the Ministry of Health, Labor and Welfare, 2016.
[31] WANG WR, GAO XF, LIU YY, et al.Validation of purity detection for Exendin-4-Fc fusion protein by SEC-HPLC[J]. Progress in Microbiology and Immunology, 2020, 48(5): 16-20.
[32] ZHOU Q, XU MM, ZHAO Q, et al.Determination of purity of antitoxin/antiserum products by high performance size exclusion chromatography[J]. Chinese Journal of Modern Applied Pharmacy(中国现代应用药学), 2021, 38(12): 1484-1489.
[33] LI XL, CUI LL, LI XN, et al.Methodology of a new potency assay of hemocoagulase[J]. Drug Standards of China(中国药品标准), 2018, 19(5): 346-352.
[34] TENG YK, KAN WN.Pontency determination of defibrase by blood coagulation analyzer[J]. China Pharmacist(中国药师), 2012, 15(6): 843-845.

蛇毒血凝酶质控关键技术研究进展

Research progress in key technologies for quality control of snake venom hemocoagulase drugs

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	辛灵怡, 杨洋, 朱婧, 何娜, 张静媚, 王航天, 陈琴华, 杨光义. 重楼抗肿瘤活性成分分类及作用机制研究进展[J]. 中国药物警戒, 2024, 21(2): 235-240.
[2]	方志娥, 李承贤, 柏兆方, 赵旭, 王伽伯, 肖小河. 马兜铃酸致肝癌的客观性研究与思考[J]. 中国药物警戒, 2024, 21(1): 20-24.
[3]	马丽娜, 胡晓祯, 郑长辉, 孙颖, 赵旭, 曹俊岭, 肖小河. 基于“因毒为能”思想的有毒中药常山毒效转化知识图谱可视化分析[J]. 中国药物警戒, 2024, 21(1): 25-32.
[4]	邰隽, 于淼, 张琳, 雷毅, 刘军廷, 李涛, 黄贵民, 程毅菁, 聂晓璐, 王青. 基于自然语言处理技术的儿童病例注射用尖吻蝮蛇血凝酶不良反应主动监测方法构建与验证研究[J]. 中国药物警戒, 2023, 20(9): 1011-1016.
[5]	杨明翰, 乔美玲, 骆骄阳, 杨美华, 盛萍. 多伞阿魏抗胃癌活性部位的急性毒性试验研究[J]. 中国药物警戒, 2023, 20(8): 880-884.
[6]	辛雨濛, 卢天公, 孙震晓. 甘草干姜汤对顺铂所致巨噬细胞毒性的保护作用[J]. 中国药物警戒, 2023, 20(6): 661-670.
[7]	张奥, 段天华, 徐荣荣, 姜晓娅, 张泽昭, 冯薇, 牛丽颖. 葛根参与淡豆豉发酵对体外抗骨质疏松活性的影响[J]. 中国药物警戒, 2023, 20(6): 671-674.
[8]	王赵, 赵剑锋, 于新兰, 金红宇, 马双成. 柴胡舒肝丸光释光法辐射筛查研究[J]. 中国药物警戒, 2023, 20(5): 514-518.
[9]	沈磐, 孙德志, 周维, 高月. 中药毒性预测研究进展与思考[J]. 中国药物警戒, 2023, 20(4): 473-479.
[10]	蔡于罗, 果佳慧, 王鑫国, 田义龙, 王梦, 牛丽颖, 李军山. 彝族药蜘蛛香的研究进展及质量标志物的预测分析[J]. 中国药物警戒, 2023, 20(3): 348-352.
[11]	王国英, 周刚, 王勤, 纪紫薇, 宁霄, 崔黎. HPLC-QE-MS技术分析盐酸倍他司汀注射液杂质谱及质量控制[J]. 中国药物警戒, 2023, 20(12): 1332-1338.
[12]	郝钢, 韩峰, 周刚, 武星, 颜皓, 李旭扬, 候海玲, 宁霄, 崔黎. 注射用腺苷钴胺细菌内毒素检查方法学研究[J]. 中国药物警戒, 2023, 20(12): 1351-1356.
[13]	谭丽媛, 蔡彤, 王岩. 化学药品标准物质定量分析方法研究进展[J]. 中国药物警戒, 2023, 20(11): 1209-1216.
[14]	黄露, 刘博, 王岩, 范慧红, 张庆生. 核苷类抗病毒药物质量控制研究进展[J]. 中国药物警戒, 2022, 19(6): 692-696.
[15]	石岩, 魏锋, 马双成. 枸橼药用研究进展[J]. 中国药物警戒, 2022, 19(5): 574-578.